Trial Profile
A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jul 2023 Planned number of patients changed from 10 to 20.
- 04 Jul 2023 Planned End Date changed from 1 Oct 2024 to 1 Jun 2025.
- 04 Jul 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Jun 2024.